Download Files:
Products Details
Product Description
– HDAC-IN-38 (compound 13) is a potent HDAC inhibitor. HDAC-IN-38 shows similar micro-molar inhibitory activity toward HDAC1, 2, 3, 5, 6, and 8. HDAC-IN-38 increases cerebral blood flow (CBF), attenuates cognitive impairment, and improves hippocampal atrophy. HDAC-IN-38 also increases the level of histone acetylation (H3K14 or H4K5)[1].
Web ID
– HY-146351
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C27H28ClN3O2
References
– [1]Kaur N, et al. Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment. Eur J Med Chem. 2020 Feb 1;187:111915.
CAS Number
– 2408123-36-2
Molecular Weight
– 461.98
SMILES
– O=C(NO)/C=C/C1=CC=C(C=C1)CNCCCN2C3=C(CCC4=C2C=C(C=C4)Cl)C=CC=C3
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– 10 mM in DMSO
Target
– HDAC
Isoform
– HDAC1;HDAC2;HDAC3;HDAC5;HDAC6;HDAC8
Pathway
– Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
